The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects
Open accessAbstract
Background Incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), play an important role in meal-related insulin secretion. We previously demonstrated that glutamine is a potent stimulus of GLP-1 secretion in vitro. Objective To determine whether glutamine increases circulating GLP-1 and GIP levels in vivo and, if so, whether this is associated with an increase in plasma insulin. Design We recruited 8 healthy, normal-weight volunteers (LEAN), 8 obese individuals with type 2 diabetes or impaired glucose tolerance (OB-DIAB) and 8 obese non-diabetic controls (OB-CON). Oral glucose (75g), glutamine (30g) and water were administered on three separate days in random order and plasma concentrations of GLP-1, GIP, insulin, glucagon and glucose were measured over 120 minutes. Results Oral glucose led to increases in circulating GLP-1 levels, peaking at 30 min in LEAN (31.9±5.7 pmol/L) and OB-CON (24.3±2.1 pmol/L) subjects and at 45 min in OB-DIAB subjects (19.5±1.8 pmol/L). Circulating GLP-1 levels increased in all study groups following glutamine ingestion, with peak levels at 30 min of 22.5±3.4 pmol/L, 17.9±1.1 pmol/L and 17.3±3.4 pmol/L in LEAN, OB-CON and OB-DIAB subjects, respectively. Glutamine also increased plasma GIP levels, but less effectively than glucose. Consistent with the increases in GLP-1 and GIP, glutamine significantly increased circulating plasma insulin levels. Glutamine stimulated glucagon secretion in all three study groups. Conclusion Glutamine effectively increases circulating GLP-1, GIP and insulin levels in vivo and may represent a novel therapeutic approach to stimulating insulin secretion in obesity and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Levy, J. C., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,013
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationInhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationIntestinal Mucosal Amino Acid Catabolism
Wu, G. (1998) · The Journal of Nutrition · doi:10.1093/jn/128.8.1249 · Cited by 836
Glutamine and the preservation of gut integrity
van der Hulst, R. R. W. J., von Meyenfeldt, M. F., Deutz, N. E. P., Soeters, P. B., Brummer, R. J. M., von Kreel, B. K., & Arends, J. W. (1993) · The Lancet · doi:10.1016/0140-6736(93)90939-e · Cited by 657
Herrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
β-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diab.40.2.166 · Cited by 585
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Self-citationOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationGastrointestinal Satiety Signals
Chaudhri, O. B., Salem, V., Murphy, K. G., & Bloom, S. R. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100506 · Cited by 334
Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells
Reimann, F., Williams, L., da Silva Xavier, G., Rutter, G. A., & Gribble, F. M. (2004) · Diabetologia · doi:10.1007/s00125-004-1498-0 · Cited by 251
Self-citationOral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy
Anderson, P. M., Schroeder, G., & Skubitz, K. M. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981001)83:7<1433::aid-cncr22>3.0.co;2-4 · Cited by 242
Safety and Metabolic Effects of L‐Glutamine Administration in Humans
Ziegler, T. R., Benfell, K., Smith, R. J., Young, L. S., Brown, E., Ferrari‐Baliviera, E., Lowe, D. K., & Wilmore, D. W. (1990) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607190014004201 · Cited by 239
Nutrient Control of Insulin Secretion in Isolated Normal Human Islets
Henquin, J.-C., Dufrane, D., & Nenquin, M. (2006) · Diabetes · doi:10.2337/db06-0868 · Cited by 228
Tremel, H., Kienle, B., Weilemann, L. S., Stehle, P., & Fürst, P. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90797-8 · Cited by 218
Reeds, P. J., & Burrin, D. G. (2001) · Journal of Nutrition · doi:10.1093/jn/131.9.2505s · Cited by 171
Stanley, S. A., Wynne, K., & Bloom, S. R. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00536.2003 · Cited by 137
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 129
Self-citationO’Donovan, D., Doran, S., Feinle‐Bisset, C., Jones, K. L., Meyer, J. H., Wishart, J. M., Morris, H. A., & Horowitz, M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0334 · Cited by 123
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
Signaling Mechanisms Underlying the Release of Glucagon-Like Peptide 1
Reimann, F. M., Ward, P. S., & Gribble, F. M. (2006) · Diabetes · doi:10.2337/db06-s010 · Cited by 79
Self-citationReview article: glucagon‐like peptide 2 – current applications and future directions
WALLIS, K., Walters, J. R. F., & Forbes, A. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03193.x · Cited by 59
Ahrén, B., Larsson, H. E., & Holst, J. J. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370127 · Cited by 57
Self-citationOral glutamine in paediatric oncology patients: a dose finding study
Ward, E., Picton, S. V., Reid, U., Thomas, D., Gardener, C., Smith, M. L., Henderson, M., Holden, V., Kinsey, S., Lewis, I. J., et al. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601517 · Cited by 47
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationMetabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans
Cheng, S., Rhee, E. P., Larson, M. G., Lewis, G. D., McCabe, E. L., Shen, D., Palma, M. J., Roberts, L. D., Dejam, A., Souza, A. L., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.067827 · Cited by 587
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Self-citationA metabolic view on menopause and ageing
Auro, K., Joensuu, A., Fischer, K., Kettunen, J., Salo, P., Mattsson, H., Niironen, M., Kaprio, J., Eriksson, J. G., Lehtimäki, T., et al. (2014) · Nature Communications · doi:10.1038/ncomms5708 · Cited by 270
Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome
Roberts, L. D., Koulman, A., & Griffin, J. L. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70143-8 · Cited by 263
Metadata
- Authors
- Greenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., & Gribble, F. M.
- Venue
- The American Journal of Clinical Nutrition
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 89
- Issue
- 1
- Pages
- 106-113
- ISSN
- 0002-9165 (ISSN-L)
- OpenAlex
- W2153965615
- Cited by
- 256
- References
- 29
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.